Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma

被引：0
|
作者：
Hewen Shi
Ying Zou
Xiaoxue Wang
Guoli Wang
Yijia Gao
Fan Yi
junqing Xu
Yancun Yin
Defang Li
Minjing Li
机构：
[1] Binzhou Medical University,Featured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Integrated Traditional Chinese and Western Medicine
[2] Binzhou Medical University,School of Basic Medical Sciences
[3] Qingdao University Medical College,Department of Hematology
[4] Affiliated Yantai Yuhuangding Hoepital,undefined
来源：
Discover Oncology | / 14卷
关键词：
Hippo pathway; Nevadensin; YAP; Sensitization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
    Chen, Kuen-Feng
    Tai, Wei-Tien
    Liu, Tsung-Hao
    Huang, Hsiang-Po
    Lin, Yu-Chin
    Shiau, Chung-Wai
    Li, Pui-Kai
    Chen, Pei-Jer
    Cheng, Ann-Lii
    CLINICAL CANCER RESEARCH, 2010, 16 (21) : 5189 - 5199
  • [22] PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
    Yang, Xiao-Dong
    Kong, Fan-En
    Qi, Ling
    Lin, Jia-Xin
    Yan, Qian
    Loong, Jane Ho Chun
    Xi, Shao-Yan
    Zhao, Yue
    Zhang, Yan
    Yuan, Yun-Fei
    Ma, Ning-Fang
    Ma, Stephanie
    Guan, Xin-Yuan
    Liu, Ming
    MOLECULAR CANCER, 2021, 20 (01)
  • [23] Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma
    Matsuda, Yasunobu
    Wakai, Toshifumi
    Kubota, Masayuki
    Osawa, Mami
    Hirose, Yuki
    Sakata, Jun
    Kobayashi, Takashi
    Fujimaki, Shun
    Takamura, Masaaki
    Yamagiwa, Satoshi
    Aoyagi, Yutaka
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (04): : 1299 - 1313
  • [24] PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
    Xiao-Dong Yang
    Fan-En Kong
    Ling Qi
    Jia-Xin Lin
    Qian Yan
    Jane Ho Chun Loong
    Shao-Yan Xi
    Yue Zhao
    Yan Zhang
    Yun-Fei Yuan
    Ning-Fang Ma
    Stephanie Ma
    Xin-Yuan Guan
    Ming Liu
    Molecular Cancer, 20
  • [25] Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells
    Hu, Yi-Ting
    Shu, Zhe-Yue
    Jiang, Jing-Hua
    Xie, Qin-Fen
    Zheng, Shu-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2020, 19 (06) : 547 - 554
  • [26] Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells
    Yi-Ting Hu
    Zhe-Yue Shu
    Jing-Hua Jiang
    Qin-Fen Xie
    Shu-Sen Zheng
    Hepatobiliary&PancreaticDiseasesInternational, 2020, 19 (06) : 547 - 554
  • [27] Clinical significance of genetic variations of Hippo-YAP pathway-related genes in hepatocellular carcinoma
    Xu, Zhi
    Shen, Lili
    Chen, Jinfei
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 : S34 - S34
  • [28] Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP
    Gao, Jian
    Rong, Yingxue
    Huang, Yuxing
    Shi, Peng
    Wang, Xitao
    Meng, Xuan
    Dong, Jiahong
    Wu, Congying
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) : 2639 - 2648
  • [29] YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis
    Gao, Ruize
    Kalathur, Ravi K. R.
    Coto-Llerena, Mairene
    Ercan, Caner
    Buechel, David
    Shuang, Song
    Piscuoglio, Salvatore
    Dill, Michael T.
    Camargo, Fernando D.
    Christofori, Gerhard
    Tang, Fengyuan
    EMBO MOLECULAR MEDICINE, 2021, 13 (12)
  • [30] KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP
    Jin, Yan
    Yang, Ruonan
    Ding, Jingyi
    Zhu, Fengqi
    Zhu, Cunle
    Xu, Qingguo
    Cai, Jinzhen
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 585 : 185 - 190
12345